Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease (ADMIRE-CD)

A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks.

The current multicentre phase III study is proposed to confirm in an add-on therapy design compared to a placebo-control group, the efficacy of adipose-derived stem cells (eASCs) from healthy donors for the treatment of complex anal fistulas in patients with Crohn's disease over a 24-week period and an extended follow-up period up to 104 weeks.

Study Overview

• Status: Completed
• Conditions: Crohn's Disease
• Intervention / Treatment: Other: Cx601; Other: Saline solution

Detailed Description

The current multicentre phase III study is proposed to confirm in an add-on therapy design compared to a placebo-control group, the efficacy of adipose-derived stem cells (eASCs) from healthy donors for the treatment of complex anal fistulas in patients with Crohn's disease over a 24-week period and an extended follow-up period up to 104 weeks. Subject with perianal fistulising Crohn's disease will be treated with Cx601, suspension of eASCs, at a dose of 120 million cells administered by intralesional injection. The treatment of complex perianal fistulas by local application of eASCs intends to improve significantly the local conditions with very few inconveniences (ambulatory procedure) and minimal risk of possible complications (anal incontinence). Therefore, this is a new therapeutic resource that is expected to be safe and efficacious as well as is expected to improve the quality of life of the patients in this highly debilitating and chronic condition. This treatment would prevent one of the main causes of anal incontinence, would diminish recurrence of the fistula disease and would reduce drastically the significant disorders provoked by the standard fistula surgery in the patients. Indeed, patients can be discharged according to the "One Day Surgical" procedures (major ambulatory surgery).

• Study Type: Interventional
• Enrollment (Anticipated): 278
• Phase: Phase 3

Contacts and Locations

Study Locations

• Austria
  • Innsbruck, Austria, 6020
    • Univ.-Klinik Innsbruck
  • St. Veit/Glan, Austria, 9300
    • Krankenhaus
  • Wien, Austria, 1090
    • Medizinische Universität
• Belgium
  • Genk, Belgium, 3600
    • Hospital Oost-Limburg
  • Gent, Belgium, 9000
    • Gent University Hospital
  • Leuven, Belgium, 3000
    • Leuven University Hospital
  • Roeselare, Belgium, 8800
    • Hospital Hartziekenhuis
• France
  • Amiens, France, 80054
    • CHU d'Amiens
  • Bordeaux, France, 3300
    • CHU de Bordeaux
  • Caen, France, 14033
    • CHU de Caen
  • Clichy, France
    • Hôpital Beaujon
  • Lille, France, 59037
    • CHRU de Lille
  • Marseille, France, 13915
    • CHU de Marseille
  • Nice, France, 06202
    • CHU de Nice
  • Paris, France
    • Hôpital Saint-Louis
• Germany
  • Berlin, Germany, 13353
    • Charité
  • Berlin, Germany, 14163
    • Krakenhaus Walfriede
  • Braunschweig, Germany, 38126
    • Klinikum Braunscheweig
  • Frankfurt/Main, Germany, 60431
    • Klinikum Frankfurt
  • Köln, Germany, 51103
    • Evangelisches Krankenhaus Kalk
  • Lüneburg, Germany, 21339
    • Klinikum Luneburg
• Israel
  • Haifa, Israel, 31096
    • Rambam MC
  • Jerusalem, Israel, 91031
    • Sharee Zedek MC
  • Petah Tikva, Israel, 49100
    • Rabin MC
  • Tel Aviv, Israel, 64239
    • Tel Aviv Sourasky MC
  • Tel Hashomer, Israel, 52621
    • Sheba MC
• Italy
  • Bologna, Italy
    • Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi
  • Firenze, Italy, 50134
    • Azienda Ospedaliero-Universitaria Careggi
  • Milano, Italy, 20089
    • Instituto Clinico Humanitas IRCCS
  • Napoli, Italy
    • Seconda Università degli Studi di Napoli
  • Padova, Italy, 35128
    • Azienda Ospedaliera Di Padova
  • Rome, Italy, 00149
    • Azienda Ospedaliera San Camillo-Forlanini
  • Rome, Italy, 00168
    • Universita Cattolica del Sacro Cuore
• Netherlands
  • Amsterdam, Netherlands
    • AMC
  • Amsterdam, Netherlands
    • VUMC
  • Eindhoven, Netherlands, 5623
    • Catharina Ziekenhuis
  • Utrecht, Netherlands
    • UMCU
• Spain
  • Barcelona, Spain
    • Hospital Clinic de Barcelona
  • Cordoba, Spain
    • Hospital Universitario Reina Sofia
  • Huelva, Spain
    • Hospital Juan Ramón Jimenez
  • Madrid, Spain, 28040
    • Fundacion Jimenez Diaz
  • Madrid, Spain, 28034
    • Hospital Ramon y Cajal
  • Madrid, Spain
    • Hospital 12 de Octubre
  • Madrid, Spain
    • Hospital Clinico San Carlos
  • Madrid, Spain
    • Hospital Universitario La Paz
  • Madrid, Spain
    • Hospital La Princesa
  • Palma de Mallorca, Spain, 07010
    • Son Espases
  • Pontevedra, Spain
    • Hospital De Montecelo
  • Seville, Spain
    • Hospital Virgen Del Rocio
  • Valencia, Spain
    • Hospital Universitario La Fe
  • Valencia, Spain
    • Hospital de Sagunto
  • Valencia
    • Manises, Valencia, Spain, 46940
      • Hospital de Manises

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

The reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.

All of them must comply with the following inclusion criteria:

1. Signed informed consent.
2. Patients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.

3. Presence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:

   • High inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.
   • Presence of ≥ 2 external openings (tracts).
   • Associated collections
4. Non-active or mildly active luminal CD defined by a CDAI ≤ 220.
5. Patients of either sex aged 18 years or older
6. Good general state of health according to clinical history and a physical examination.
7. For women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.

Exclusion Criteria:

1. Presence of dominant luminal active Crohn's disease requiring immediate therapy.
2. CDAI >220.
3. Concomitant rectovaginal fistulas
4. Patient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics
5. Presence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).
6. Presence of > 2 fistular lesions.
7. Presence of > 3 external openings.
8. Rectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.
9. Patient who underwent surgery for the fistula other than drainage or seton placement.
10. Patient with diverting stomas
11. Patient with ongoing steroid treatment or treated with steroids in the last 4 weeks
12. Renal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)

13. Hepatic impairment defined by both of the following laboratory ranges:

    • Total bilirubin ≥ 1.5 x ULN
    • Aspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN
14. Known history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.
15. Malignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.
16. Current or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.
17. Congenital or acquired immunodeficiencies.
18. Known allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).
19. Contraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).
20. Major surgery or severe trauma within the previous 6 months.
21. Pregnant or breastfeeding women.
22. Patients who do not wish to or cannot comply with study procedures.
23. Patients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.
24. Patients previously treated with eASCs can not be enrol into this clinical study.
25. Subjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.
26. Contraindication to the anaesthetic procedure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Arm; Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.	Other: Cx601; 120 million cells administered by intralesional injection.
Placebo Comparator: Placebo-control group; Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.	Other: Saline solution; 24 mL saline solution by intralesional injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Combine remission of perianal fistulising Crohn's	Combined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy Assessment by week 24	Clinical Remission (CR) defined as closure of all treated EO that were draining at baseline despite gentle finger compression, as clinically assessed; Response defined as closure of at least 50% of all treated EO that were draining at baseline, as clinically assessed; Time to Clinical Remission (time from treatment start to 1st visit with closure of all treated EO as described above); Time to Response (time from treatment start to 1st visit with closure of at least 50% of all treated EO as described above); Relapse defined, in patients with CR at previous visit, as reopening of any of the treated EO with active drainage, or the development of a perianal collection > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI; Time to Relapse in patients with CR (time from CR to 1st visit with reopening of any of the treated EO as described above); Severity of the perianal CD, assessed with the PDAI; QoL assessed by IBDQ; CDAI score; Van Assche	24 weeks
Efficacy Assessment by week 52	Combined Remission of perianal fistulising Crohn's disease at week 52 (as defined for week 24); Clinical Remission defined as the closure of all treated external openings that were draining at baseline despite gentle finger compression, as clinically assessed at week 52; Response defined as closure of at least 50% of all treated external openings that were draining at baseline, as clinically assessed at week 52; Time to Combined Remission by week 52 (as defined for week 24); Time to Clinical Remission by week 52 (as defined for week 24); Time to Response by week 52 (as defined for week 24); Relapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24); Time to Relapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24); Severity of the perianal Crohn's disease up to week 52 assessed PDAI; QoL up to week 52 by the IBDQ; CDAI score up to week 52; Van Assche score up to week 52	52 weeks
Efficacy Assessment by week 104	Clinical Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings that were draining at baseline despite gentle finger compression at week 104; Relapse by week 104 in patients with Combined Remission at week 52, defined as reopening of any of the treated external openings with active drainage as clinically assessed; Time to Relapse by week 104 in patients with Combined Remission at week 52 (defined as time from Combined Remission to first visit with reopening of any of the treated external openings with active drainage as clinically assessed); Severity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI) up to week 104; Quality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) up to week 104; CDAI score up to week 104	104 Weeks
Safety analysis throughout the study:	Adverse events including: Treatment emergent Adverse Events (TEAEs), TEAEs related to study treatment, Treatment emergent Serious Adverse Events (TESAEs), TESAEs related to study treatment, TEAEs leading to study withdrawal, adverse events related to surgical procedure(s) to provide study treatment, deaths Only SAEs will be reported during the 2nd follow-up period between week 52 and week 104.; Physical examination; Vital signs; Laboratory tests (biochemistry, haematology, urinalysis)	week 24, 52 and 104

Collaborators and Investigators

• Sponsor: Tigenix S.A.U.
• Investigators: Study Chair: Julian Panes, MD, Hospital Clinic of Barcelona; Principal Investigator: Julian Panés, MD, Hospital Clinic of Barcelona; Principal Investigator: Lili Kazemi-Shirazi, Professor, Medical University of Vienna; Principal Investigator: Karl Mrak, MD, Krankenhaus, St. Veit/Glan; Principal Investigator: Marc Ferrante, MD, Universitaire Ziekenhuizen KU Leuven; Principal Investigator: Kurt Van der Speeten, MD, Hospital Oost-Limburg, Genk; Principal Investigator: Danny de Looze, Professor, Gent University Hospital; Principal Investigator: Filip Baert, MD, Hospital Hartziekenhuis, Roeselare; Principal Investigator: Daniel C Baumgart, Professor, Charite University, Berlin, Germany; Principal Investigator: Axel Dignass, Professor, Kilikum Frankfurt; Principal Investigator: Max Reinshagen, Professor, Kinikum Braunschweig; Principal Investigator: Silvio Danese, MD, Instituto Clinico Humanitas IRCCS, Milano; Principal Investigator: Vito Annese, MD, Azienda Ospedaliero-Universitaria Careggi, Firenze; Principal Investigator: Anna Kohn, MD, Azienda Ospedaliera San Camillo-Forlanini, Rome; Principal Investigator: Alfredo Papa, MD, Università Cattolica del Sacro Cuore, Rome; Principal Investigator: Giacomo C Sturniolo, Professor, Azienda Ospedaliera Di Padova; Principal Investigator: Andrea Belluzi, MD, Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi; Principal Investigator: Gabriele Riegler, Professor, University of Campania "Luigi Vanvitelli"; Principal Investigator: Bas Oldenburg, MD, UMCU, Utrecht; Principal Investigator: Adriaan A van Bodegraven, MD, Amsterdam Umc, Location Vumc; Principal Investigator: Gigs van den Brink, Professor, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Principal Investigator: María D Martín Arranz, MD, Hospital Universitario La Paz; Principal Investigator: Jose M Gallardo Valverde, MD, Hospital Universitario Reina Sofia, Cordoba; Principal Investigator: Javier Pérez Gisbert, MD, Hospital La Princesa (Madrid); Principal Investigator: Belén Beltrán Niclós, MD, Hospital Universitario La Fe; Principal Investigator: Carlos Taxonera Samsó, MD, Hospital Clínico San Carlos, Madrid; Principal Investigator: Fernando de la Portilla de Juan, MD, Hospital Virgen del Rocío, Seville; Principal Investigator: Ricardo Rada Morgades, MD, Hospital Juan Ramón Jiménez, Huelva; Principal Investigator: Gonzalo Gómez Gómez, MD, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, MADRID; Principal Investigator: Daniel Carpio López, MD, Hospital de Montecelo, Pontevedra; Principal Investigator: Xavier Cortés Rizo, MD, Hospital de Sagunto, Valencia; Principal Investigator: Torsten Kucharzik, Professor, Klinikum Luneburg; Principal Investigator: Andreas Sturm, Professor, Krakenhaus Walfriede, Berlin; Principal Investigator: Antonio López Sanromán, MD, Hospital Universitario Ramón y Cajal; Principal Investigator: Joaquín Hinojosa de Val, MD, Hospital de Manises, Valencia; Principal Investigator: Xavier González Argenté, MD, Son Espases, Palma de Mallorca; Principal Investigator: Maria Nachury, MD, CHRU de Lille; Principal Investigator: Frank Zerbib, MD, CHU Bordeaux; Principal Investigator: Stéphanie Viennot, MD, University Hospital, Caen; Principal Investigator: Jean-Louis Dupas, MD, Centre Hospitalier Universitaire, Amiens; Principal Investigator: Jean-Charles Grimaud, MD, CHU de Marseille; Principal Investigator: Xavier Hebuterne, Professor, Centre Hospitalier Universitaire de Nice; Principal Investigator: Matthieu Allez, Professor, Hôpital Saint Louis Paris; Principal Investigator: Yoram Bouhnik, MD, Hopital Beaujon, Clichy; Principal Investigator: Matti Waterman, MD, Rambam MC, Haifa; Principal Investigator: Shomron Ben-Horin, MD, Sheba MC, Tel Hashomer; Principal Investigator: Sigal Fishman, MD, Tel Aviv Sourasky MC, Tel Aviv; Principal Investigator: Eran Goldin, Professor, Sharee Zedek MC, Jerusalem; Principal Investigator: Irit Avni-Biron, MD, Rabin MC, Petah Tikva; Principal Investigator: Herbert Tilg, Professor, Univ.-Klinik Innsbruck; Principal Investigator: Lennard Gilissen, MD, Catharina Ziekenhuis Eindhoven; Principal Investigator: Carlos Pastor, MD, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Principal Investigator: Wolfgang Kruis, Professor, Evangelisches Krankenhaus Kalk, Köln

Publications and helpful links

General Publications

• Garcia-Olmo D, Gilaberte I, Binek M, D Hoore AJL, Lindner D, Selvaggi F, Spinelli A, Panes J. Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial. Dis Colon Rectum. 2022 May 1;65(5):713-720. doi: 10.1097/DCR.0000000000002325.
• Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2018 Apr;154(5):1334-1342.e4. doi: 10.1053/j.gastro.2017.12.020. Epub 2017 Dec 24.
• Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29.

Study record dates

Study Major Dates

• Study Start: July 1, 2012
• Primary Completion (Actual): July 1, 2015
• Study Completion (Actual): November 1, 2016

Study Registration Dates

• First Submitted: February 21, 2012
• First Submitted That Met QC Criteria: February 29, 2012
• First Posted (Estimate): March 1, 2012

Study Record Updates

• Last Update Posted (Actual): November 29, 2019
• Last Update Submitted That Met QC Criteria: November 27, 2019
• Last Verified: November 1, 2019

More Information

Terms related to this study

• Keywords: Perianal fistulising Crohn's disease.
• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; Inflammatory Bowel Diseases; Crohn Disease
• Other Study ID Numbers: Cx601-0302

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No